TY - JOUR
T1 - Nanoparticle-mediated corneal neovascularization treatments
T2 - Toward new generation of drug delivery systems
AU - Zhu, H.
AU - Yu, J.
AU - Ye, J.
AU - Wu, Y.
AU - Pan, J.
AU - Li, Y.
AU - Chen, C.
AU - Zheng, L.
AU - Liu, G.
AU - Chu, Chengchao
N1 - This work was supported by the National Natural Science Foundation of China (NSFC, Nos. 81901876, 81925019, 81801817, and U1705281), Guangdong Basic and Applied Basic Research Foundation (No. 2114050002159), Shenzhen Science and Technology Program (No. JCYJ20210324121801004), National College Student Innovation and Entrepreneurship Training Program (No. 202012631001).
PY - 2023/3
Y1 - 2023/3
N2 - Corneal neovascularization (CNV) is one of the major factors for vision impairment and blindness worldwide. The current treatment for CNV focuses primarily on topical eyedrops of glucocorticoids, non-steroidal anti-inflammatory drugs, electro-coagulation and laser photo-coagulation. Unfortunately, coagulation-based treatment is restricted by corneal hemorrhage and iris atrophy. And drug treatments have limited therapeutic effects and a short duration of action. Nanoparticle-based drug delivery systems are widely applied due to their improved pharmacokinetics, optimized drug targeting and enhanced biocompatibility. In this article, we provide a comprehensive and systematic overview of the CNV nanodrug system, highlighting some of the recent advances in nanodrug design, preparation, and functional modification. Moreover, we discuss the challenges in the clinical translation and potential risks in CNV treatment. A greater effort is needed for the potential applications of nanotechnology in the field of ophthalmology.
AB - Corneal neovascularization (CNV) is one of the major factors for vision impairment and blindness worldwide. The current treatment for CNV focuses primarily on topical eyedrops of glucocorticoids, non-steroidal anti-inflammatory drugs, electro-coagulation and laser photo-coagulation. Unfortunately, coagulation-based treatment is restricted by corneal hemorrhage and iris atrophy. And drug treatments have limited therapeutic effects and a short duration of action. Nanoparticle-based drug delivery systems are widely applied due to their improved pharmacokinetics, optimized drug targeting and enhanced biocompatibility. In this article, we provide a comprehensive and systematic overview of the CNV nanodrug system, highlighting some of the recent advances in nanodrug design, preparation, and functional modification. Moreover, we discuss the challenges in the clinical translation and potential risks in CNV treatment. A greater effort is needed for the potential applications of nanotechnology in the field of ophthalmology.
UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-85144996044&partnerID=MN8TOARS
U2 - 10.1016/j.cclet.2022.06.071
DO - 10.1016/j.cclet.2022.06.071
M3 - Article
SN - 1001-8417
VL - 34
JO - Chinese Chemical Letters
JF - Chinese Chemical Letters
IS - 3
M1 - 107648
ER -